Vaxart, Inc. – Press Releases

Search

Year

August 02, 2024

Vaxart to Host Second Quarter 2024 Business Update and Financial Results Conference Call on August 8

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. , Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the second quarter ended June 30, 2024 after the market close on Thursday, August

June 17, 2024

PDF Version

Vaxart Provides Business Update

— Cash runway extended into 2026 — — Received one of the largest BARDA-funded Project NextGen Awards to date, up to $453 million — — Company well-capitalized to execute on multiple key clinical and regulatory milestones in COVID-19 and norovirus programs — SOUTH SAN FRANCISCO, Calif.

June 13, 2024

PDF Version

Vaxart Announces $40 Million Underwritten Offering of Common Stock

SOUTH SAN FRANCISCO, Calif. , June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per share.

June 13, 2024

PDF Version

Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

— 10,000-subject Phase 2b study will evaluate Vaxart’s next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator — — Vaxart anticipates initiating enrollment as early as summer 2024 — SOUTH SAN FRANCISCO, Calif. , June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc.

May 23, 2024

PDF Version

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , May 23, 2024 (GLOBE NEWSWIRE) -- Vaxart , Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that on May 17, 2024 , the Compensation Committee of the Board of Directors granted inducement equity awards covering an aggregate of 22,500 shares of its common

May 13, 2024

PDF Version

Vaxart Provides Business Update and Reports First Quarter 2024 Financial Results

Positive results from Phase 1 norovirus study in lactating mothers indicate the potential of Vaxart’s oral pill vaccine candidate to protect or reduce the effect of the disease in infants Expects to initiate Phase 2b study evaluating Vaxart’s oral pill XBB COVID-19 vaccine against an approved

May 07, 2024

PDF Version

Vaxart to Host First Quarter 2024 Business Update and Financial Results Conference Call on May 13

Conference call to begin at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. , May 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the first quarter ended March 31, 2024 after the market close on Monday, May 13,

April 30, 2024

PDF Version

Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers

Antibody rise observed in lactating mothers and in their breast milk Long-term goal is to provide protection to infants through passive antibody transfer SOUTH SAN FRANCISCO, Calif. , April 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has completed the topline

March 27, 2024

PDF Version

Vaxart to Present at World Vaccine Congress Washington 2024 on April 3

SOUTH SAN FRANCISCO, Calif. , March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker , Founder and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2024 in Washington, D.C. on Wednesday, April 3, 2024 .

March 20, 2024

PDF Version

Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif. , March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the Compensation Committee of the Board of Directors approved certain equity awards to the Company’s new President and Chief Executive Officer, Steven Lo ,

Pagination

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Press Releases.

Search